Within-Patient Comparison of Serum Transthyretin Response to Tafamidis Versus Acoramidis: A Pilot Crossover Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Condition studied

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational medicinal product(s)

Eligibility

Primary endpoint

The primary endpoint of this study is the absolute change in serum TTR concentration (mg/dL) from baseline (pre-dose, day 0) to week 4 (day 28 ±5) after initiation of treatment with tafamidis and acoramidis. The pre-specified primary endpoints are the absolute change, with relative (%) change reported as supportive.